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Background: Antiretroviral therapy (ART) reduces HIV-related mortality and morbidity substantially in children. The
clinical characteristics, immunological and virological outcomes were evaluated in HIV-infected children receiving
ART.
Methods: Twenty-six HIV-1-infected children receiving ART in Hubei province, China, were enrolled retrospectively
in this study. During the period of ART, plasma viral load, lymphocyte phenotype of CD4 and CD8 cells and clinical
events were assessed.
Results: The median duration of ART was 41 months (18–72.3 months). In children showing clinical improvement,
high viral suppression rate below log10 (2.7) copies/ml by the third months of ART was observed. The median CD4
cell counts reached to 820.5/μl by 12 months and the median ratio of CD4/CD8 increased to 0.6 by 21 months. The
counts of peripheral white blood cells and red blood cells decreased in the first 12 months, while Hb concentration,
MCV and MCH increased (P < 0.001).
Conclusions: Despite the limited small sample size, ART is an effective strategy for inhibiting HIV replication and
reconstructing the immunological response in children with AIDS.
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Antiretroviral therapy (ART) reduces HIV-related mortal-
ity and morbidity substantially in children, and without
HIV care, the progression of HIV-infection children is
particularly aggressive. The World Health Organization
(WHO) guidelines recommended initiating ART in all
children according to their clinical stage and CD4 cell
count or percentage [1]. However, long-term therapy can
adversely affect a child’s quality of life because of the regi-
men’s side effects [2] and ART resistance [3] which may
result in growth faltering, stunting, especially once they
reach adolescence [4,5].
The Division of Treatment and Care (DTC) of the
National Center for AIDS/STD Control of China esti-
mated nearly 6000 children infected with HIV-1 in China
at the end of 2011 [6]. Before 2005, few HIV-infected
children in China received ART, and pediatric formula-
tions were unavailable by referring to adult fixed-dose* Correspondence: zhao_wh2004@hotmail.com
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article, unless otherwise stated.combinations [7-9]. The DTC initiated the National
Pediatric Free ART Program (NPFAP) in June 2005. Hubei,
a central province in China, was one of the first eight trial
units to undertake this program. In the present study the
short term virological, immunological and clinical out-
comes of HIV infected children with ART was evaluated
from pediatric HIV care program in central China.Methods
Enrolment and study setting based on the WHO clinical
and laboratory criteria [1], 26 of 68 HIV-1-infected
Chinese children were eligible for free ART formulations
and enrolled in this cohort. The NPFAP was performed at
the HIV/AIDS Treatment Center of Zhongnan Hospital,
Wuhan University in Hubei province, China. This prog-
ramme is supported by the Chinese Center of Disease
Control, which started to provide free access to pediatric
antiretroviral therapy in China. The programme included
prophylaxis and treatment for opportunistic infections,
psychosocial support, nutritional support, and antiretro-
viral treatment.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Characteristics of children started on




Age at start ART (years, median)a 7.7 (1.5–12)
<2 years 2 7.7%
2–4.9 years 4 15.3%
5–14 years 20 77%
Sex (male/female) 16/10 61.5%/38.5%
Reason for ART
WHO stage III-IV 6 36.5%
Baseline CD4 count <15% 20 63.5%
Naïve ART regimen
D4T/3TC/NVP (EFV) 8 30.8%
AZT/3TC/NVP 18 69.2%
Time on ART (months, median)a,b 41 (18–72.3)
<2 yearsb 5 19.2%
2 years to <3 yearsb 7 26.9%
3 years to <4 yearsb 6 23.1%
>4 yearsb 8 30.8%
HIV transmission
Blood product or transfusion recipient 9 34.6%
Mother-to-child transmission 17 65.4%
aValues are expressed as median (interquartile range).
bAs of 30 December 2008 (closing date of dataset).
WHO, World Health Organization; ART, antiretroviral therapy; D4T, stavudine;
3TC, lamivudine; AZT, zidovudine;NVP, nevirapine; EFV, efavirenz.
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lines [1]. HIV-infected children presenting with WHO
stage I or II were eligible for ART if the CD4 cell
counts <350 cells/μl or CD4% <15% for children >3 years
old, CD4 cell counts <750 cells/μL or CD4% <20% for
children 1–3 years old, or virologically diagnosed chil-
dren <1 year old regardless of CD4 cell count or CD4%.
Children presenting with WHO stage III/IV were eligible
irrespective of their CD4 percentage or CD4 count. First-
line ART comprised the nucleoside reverse transcript-
ase inhibitors (NRTIs) zidovudine (AZT) or stavudine
(D4T) plus lamivudine (3TC), and the non-nucleoside re-
verse transcriptase inhibitors (NNRTIs) nevirapine (NVP)
or efavirenz (EFV) for all eligible children. The protease
inhibitor (PI) lopinavir/ritonavir was as the second line
preparation. Of 26 HIV-infected children, eight had been
treated with D4T, 3TC and NVP or EFV, and their treat-
ments were adjusted to the free regimens of AZT, 3TC
and NVP at the time of entry into the programme of
eighteen ART-naïve HIV children in 2005. The clinical
and laboratory data collected at baseline were analyzed for
all children enrolled.
Laboratory data collection
Blood samples were collected in the morning and proc-
essed the same day at Wuhan University HIV/AIDS Treat-
ment Center. CD4 and CD8 cell counts were measured
using the single-platform assay in a FACSCalibur flow cyt-
ometer (Becton Dickinson, Aalst, Belgium). The CD4 per-
centage was calculated using the formula: CD4% = absolute
CD4 count/(white blood cell (WBC) count × percentage of
lymphocytes). An absorbance cytochemistry and haematol-
ogy analyser (Coulter Beckman, Fullerton, CA, USA) was
used to measure haematological parameters including
hemoglobin concentration (Hb), red blood cell (RBC), and
red cell indices such as mean corpuscular volume (MCV),
mean corpuscular Hb content (MCH), as well as mean cor-
puscular Hb concentration (MCHC). Viral load (VL) was
detected by a real-time reverse transcriptase polymerase
chain reaction (Roche Molecular Systems, Branchburg, NJ,
USA). Therapeutic failure was defined as a low CD4 cell
count according to the WHO criteria or an increase in VL
to > log10 (3.7) copies/ml [1]. The limit of quantification
(LOQ) was log10 (2.7) copies/ml. Body weight and height
were collected and monitored at baseline, monthly in first
three months, and every three months thereafter.
This program used the Free ART database to monitor
current and past patients in this Program. Information was
collected at the time of treatment initiation, each follow-up
visit, regimen change, and treatment termination.
Data analysis
Analysis of data was performed by on-treatment analysis
of the observed data. Z-scores (standard deviation scores)are calculated as (variable-mean)/standard deviation. Stat-
istical analysis was performed using SPSS 19.0 software
(SPSS Inc, Chicago, IL, USA). All tests were two-tailed
with P-values <0.05 considered significantly.
Ethical approval
This study was approved by the Institutional Review
Board of the National Center for AIDS/STD Control
and Prevention, Chinese Center for Disease Control and
Prevention. All parents of patients signed informed con-
sent for participation.
Results
Characteristics of HIV-1-infected children
General characteristics are shown in Table 1. Eight
(31%) HIV-1-infected children received ART (D4T,
3TC and EFV) at baseline for 1–3 years until June
2005, and then their therapy was changed into the free
ART regimens of AZT, 3TC and NVP. Six children had
been diagnosed with AIDS stage III–IV and the other
twenty children had moderate-to-severe immunosup-
pression and a CD4 T cell percentage <15-20%. Twenty-
four (92%) of the 26 children had a detectable VL > log10
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years (1.7–12 years), and the latent infection time was
6.8 years (1.4–11.5 years). Nine children had been in-
fected through blood products or transfusion, and four
of these had coinfected hepatitis C virus. Seventeen
children had been infected through mother-to-child
transmission. The median duration of administration of
ART was 41 months. In the follow up time, two (8%)
children died (one due to severe diarrhea diseases and
by non-AIDS related cases). One child had an immuno-
logical and virological failure and the second line ART
regime contains NVP plus lopinavir/ritonavir was initi-
ated after 41 months on ART. By the end of a median
time of 41 months, 24 children (92%) were alive and re-
ceiving ART.
ART and immunologic outcomes
The baseline median CD4 count was 115.7 cells/μl,
and this count increased markedly to 268.5 cells/μl
in the third month and reached its highest level of
810.4 cells/μl at the first year of ART (Figure 1). The
CD4 count increased to 1.8-fold by the middle of the first
month and reached its highest level of 6.9-fold in the
ninth month. CD4 percentage increased from 12% to
25% in the sixth month and was maintained >34% in the
ninth month. Two patients demonstrated failure to ART
in the third year. Before the free ART program, both
had been treated with D4T, 3TC and NVP/EFV, and
their CD4 cell counts decreased to 95 and 97 cells/μl at
the end of the third year when they showed resistance
to the AZT/3TC/NVP protocol. One died of profound
diarrhea after 42 months of ART. The other was given
NVP plus LPV/RTV, and the absolute CD4 cell count
increased markedly from 10 to 750 cells/μl within six
months. Twenty-four (92%) of the 26 HIV-infected chil-
dren achieved immunological advantage from this free
ART.Figure 1 Antiretroviral therapy and CD4+ T cell counts. Data exclude tART and virological outcomes
At the beginning of this study, the VL mean was log 10
(5.9 ± 3.2) copies/ml. In 23 children, the VL decreased to
less than log10 (2.7) copies/ml within 3 months of ART
and VL was maintained at this level until the preparation
of this study (Figure 2). Two HIV-infected children who
had received ART before the free regimen appeared to
treatment failure with high VL levels > log10 (4.7) cop-
ies/ml at 36 months. One was given NVP plus LPV/
RTV, and the VL decreased to an undetectable level after
three months, while the CD4 count increased to 750/μl
after six months. As results, the combination of AZT/
3TC/NVP was effective in suppressing HIV replication
in most HIV infected children.
ART and growth
At the beginning of ART, the mean Z-scores of HIV-1-
infected children’s body weight and height for age
were –0.33 and –0.17 (Figure 3), compared those with
the general population standards of Chinese children
(P < 0.001). Figure 3 shows that 23 of the 26 children
achieved quick recovery growth in the first year, after
which their growth velocity was the same as in healthy
childhood. The two children virological failure with in-
creased VL stunted growth had Z-scores of –0.35, –
0.33 and –0.26, –0.23 for weight and height after the
third year of ART. One was changed to NVP plus LPV/
RTV and recovered a normal growth rate. By the end of
41 months of time, the increase in body weight and
height of 23 children was associated with positive clin-
ical outcomes.
ART and adverse events
All children had mild to moderate anemia at the begin-
ning of ART. At the end of the first year of ART, Mean
Hb had increased from 107.9 ± 13.7 g/L to 112.2 ± 11.2
g/L (P < 0.001). In contrast, Mean of red blood cell countwo children who had ART treatment failure and shown as median.
Figure 2 Summary of viral load and the percentage of CD4 T cell during follow-up after antiretroviral therapy. The values are the mean
of log 10 (copies/ml) and CD4 T cell percentage.
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(P < 0.001). All children demonstrated a change to
megaloblast-like red blood cell (Figure 4). The base-
line means of WBC and the lymphocyte counts were
5.1 ± 1.3 × 109/L and 2.0 ± 0.7 × 109/L. After 12 months
of ART, the WBC count decreased to 4.4 ± 0. 8 × 109/L
(P = 0.04), and the lymphocyte count decreased to
1.8 ± 0.6 × 109/L (P = 0.02). Of the patients with se-
vere anemia, none required a change of regimen be-
cause of symptomatic anemia or blood transfusions.
Other haematological parameters evaluation included
macrocytosis and thrombocytopenia (Figure 4). Mac-
rocytosis was identified in all patients on ART compared
with their baseline level (P < 0.001). All patients had an
MCV >100 fl. However, there was no clinical conse-
quence of macrocytosis in these patients. No patient
exhibited thrombocytopenia or liver dysfunction during
ART.Figure 3 Changes of mean Z-scores for body weight and height for aDiscussion
Our study shows that ART (AZT/3TC/NVP) should be
effective in achieving an adequate response in HIV-
infected children. Most HIV-children showed improved
clinical, immunological and virological outcomes. Such
therapy results are similar to those reported for adults [10]
and a small cohort of older children in resource-limited
settings [11]. These responses were greater than those re-
ported in severe immunosuppression settings [12,13].
The immunological outcomes from receiving ART
showed evidence of significant immunological reconstitu-
tion in most of the cohort. After 12 months of ART, most
HIV-infected children with available CD4 cell percentage
data attained near-normal immune status (e.g. CD4 cell
percentage of 34%). The CD4 cell counts increased to the
highest level in the first year, and children with the most
profound immunosuppression at the onset had the great-
est increases in CD4 cell count (from 17 to 510 cells/μl).ge in children receiving antiretroviral therapy.
Figure 4 Changes in red blood cell parameters in children receiving antiretroviral therapy. RBC, red blood cell; MCV, mean corpuscular
volume; MCH, mean corpuscular Hb content, and MCHC, mean corpuscular Hb concentration. The values are expressed as mean ± SD. * P < 0.001.
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CD4 cell counts, and a significantly higher proportion ex-
perienced an opportunistic infection. This suggests that,
although immune function improves significantly in
these children irrespective of the baseline CD4 cell count
and percentage, the greater the baseline immunodefi-
ciency, the more likely the patient will remain at risk of
opportunistic infections during the first year of receiving
ART [14].
The survival rate is determined mainly by age-risk in
the first six months of ART, whereas the patient’s sex,
baseline CD4 cell percentage, baseline WHO clinical
stage and initial drug regimens are not significantly asso-
ciated with death in different age groups [15]. Our data
show a survival probability of 92.3%, which is greater
than that reported in large trials in Africa [16]. One rea-
son for this difference could be the small samples size in
our study and that most of these HIV-infected children
were older than two years.
Our results are similar to those from resource-rich
settings [17], although the children from resource-
rich settings were mainly ART non-native and less
immunosuppressed, and were treated mainly with prote-
ase inhibitor-containing regimens [2]. These data suggest
that better outcomes are achieved regardless of when
ART is started provided it is started before profound
immunosuppression develops [16]. In resource-limited
settings, under routine programme conditions, giving
NNRTI-containing ART to severely and profoundly im-
munosuppressed children can achieve good early out-
comes. This provides further impetus to the urgency of
ensuring that children in resource-limited settings have
early access to life-prolonging ART. Virological evidence
is an advantage in assessing therapeutic responses [18].
In this study, the mean baseline VL decreased to below
the LOQ after three months of ART. Two children devel-
oped virological failure, and their VLs increased afterthree years of therapy. One child’s regimen was changed
by substituting D4T with AZT, but viral replication could
not be suppressed and the absolute CD4 cell count de-
clined to 20/μl, and the child died of severe diarrhea in
the fourth year. Another child’s regimen was changed to
NVP plus lopinavir/ritonavir, to our surprise, the CD4
cell count rebounded from 10/μl to 750/μl, and VL was
below the LOQ after six months despite frequent respira-
tory tract infections. This is important because it suggests
that LPV/RTV is more effective in a child undergoing
ART with virological and immunological failure [19].
HIV-infected children are significantly shorter and
lighter than healthy children, and the growth differences
increase with age [4]. Our data show that baseline age
Z-scores for weight and height were –0.33 and –0.17 re-
spectively, and that height and weight increased in all
children who received ART. Z-scores for weight and
height increased to nearly 0 during the three years after
initiation of combination therapy. Growth velocity was
greater in HIV-infected children with ART than in
healthy children especially in the first year of treatment.
Initiation of ART improves the mean standardized weight-
for-age Z-score and weight-for-age percentiles [20]. These
results suggest that combination therapy in severely HIV-
infected children helps increase weight and, to a lesser ex-
tent, height and that children experience a continued
catch-up in weight and height after starting ART [5].
ART causing macrocytic anemia has been reported
elsewhere [21]. Macrocytosis was associated with ART,
and all children on ART had increase level of MCV and
MCH, whereas MCHC did not change. Anemia is com-
mon in HIV-infected children, and this probably reflects
the multifactorial causes involved in the pathogenesis.
ART drugs such as AZT and D4T are associated with a
transient macrocytic anemia by inhibiting β-globin gene
expression in human erythroid progenitor cells [22,23].
Usually, the hemoglobin A2 concentration may be high
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the clinician is not aware of this unexpected effect of
HIV infection and its treatment. Despite this, macrocy-
tosis had no clinical consequence and ART increased
the CD4 cell count and decreased the total lymphocyte
count.
Conclusions
In conclusion, despite the limited small sample size,
ART is an effective strategy for inhibiting HIV replica-
tion and reconstructing the immunological response in
children with AIDS.
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